Sinaptica Therapeutics™ https://validator.w3.org/feed/docs/rss2.html Sinaptica Announces Initiation of Co-Development of the SinaptiStim® Precision Neuromodulation System to treat Alzheimer’s Disease; On Track for Pivotal Clinical Trial Initiation in 2025 Home Harald Hampel MD, PhD, MSc Yohannes Iyassu Simone Rossi, MD, PhD Are we entering a neurotechnology renaissance in healthcare? PUBLICATIONS Greg Harper Sinaptica Therapeutics Completes Scientific Advisory Board, Bringing Together Leading Voices Across Patients, Science, Medicine, and Commercial Strategy Jim Schwoebel Alessio Travaglia The neurobiological foundation of effective repetitive transcranial magnetic brain stimulation in Alzheimer’s disease Effects of 52 weeks of precuneus rTMS in Alzheimer’s disease patients: a randomized triala Macro and micro structural preservation of grey matter integrity after 24 weeks of rTMS in Alzheimer’s disease patients: a pilot study Precuneus magnetic stimulation for Alzheimer’s disease: a randomized, sham-controlled trial Sinaptica Therapeutics Receives Funding from The Centre for Aging + Brain Health Innovation and Baycrest to Advance Breakthrough Neuromodulation Therapy for Alzheimer’s News Precision Neuromodulation Decreased Brain Atrophy and Increased Connectivity in Key Brain Network in Alzheimer’s Patients Mark Wang Enrollment Initiated for Phase 2 Clinical trial in Early Alzheimer’s with Sinaptica’s Second-Generation Precision Neuromodulation System Targeted Magnetic Stimulation Slows Alzheimer’s Progression in Phase II Study FDA breakthrough device designation stimulates increased interest Early neurotechnology trials have seen some success. Here are the details. Small mid-stage trial suggests targeted magnetic pulses to brain could slow Alzheimer’s How Personalized Repetitive Transcranial Magnetic Stimulation May Transform Alzheimer Treatment Publication in Alzheimer’s & Dementia Elucidates Multimodal Mechanism of Action Underpinning Promising New Neuromodulation Therapy for Alzheimer’s SCIENCE Jim Taylor Lisa Fosdick Sinaptica FDA Breakthrough Device Designation Positive Data Published in Alzheimer’s Research & Therapy from 12-month Phase 2 Study in Alzheimer’s Using Personalized Neuromodulation Therapy; Trial Met All Primary and Key Secondary Endpoints Alzheimer’s researchers say brain stimulation device may slow symptoms Personalized Neuromodulation Treatment Significantly Slowed Alzheimer’s Progression in 12-month Phase 2 Study, Meeting Primary and Key Secondary Endpoints TMS-EEG perturbation biomarkers for Alzheimer’s disease patients classification Alzheimer’s Disease: Can Machine Learning Fix a Broken Brain Network? Sinaptica Therapeutics: MedTech Upstart Takes on Alzheimer’s with Radical New Approach It’s not just about plaques: rTMS also reduces cognitive and functional decline in Alzheimer’s Noninvasive Brain Stimulation Shows Potential Repetitive TMS to the Precuneus Stabilizes Cognitive Status Shaping the Future of Alzheimer’s Care: Interview with Sinaptica CEO Ken Mariash Alzheimer’s: Approaching a Cure Sinaptica’s Breakthrough Device Could Slow Brain Atrophy In Alzheimer’s Patients – Study Sinaptica On Precision Neuromodulation To Combat Alzheimer’s: ‘No Drug Dares Go After Moderate Patients’ StartUp Health – Sinaptica Therapeutics: Bridging Neuroscience Gaps to Slow the Progression of Alzheimer’s Disease Noninvasive brain stimulation slows Alzheimer’s disease in yearlong trial Personalized Noninvasive Neuromodulation Slows AD Progression Positive Phase II Alzheimer’s trial results Published Sinaptica Appoints Ken Mariash CEO Sinaptica Completes Scientific Advisory Board with Final Expert Appointment as Company Advances to Pivotal Trial in Alzheimer’s Sinaptica Therapeutics Selected for StartUp Health’s Alzheimer’s Moonshot